Harnessing gallium’s unique molecular biology to drive next-generation therapeutics in medical oncology and infectious diseases.
MedResearch began in Australia with a singular purpose: to investigate the therapeutic promise of advanced Medical Gallium Therapeutics (MGT), metal-based molecules overlooked by modern researchers, despite their low toxicity and compelling anti-tumour activity. These foundational features anchors our mission to develop practical, quality-of-life–enhancing medical innovations.
We aspire to create a new paradigm in medical research, one where success is measured by lives saved. A society where accessible, evidence-based treatments are the norm, not the exception.
Medical Gallium Therapeutics (MGT), still in early-stages of clinical research, are well-tolerated compounds demonstrating exciting potential to inhibit cancer cell growth and reduce inflammation, particularly in difficult-to-treat brain and liver cancers. We are committed to leading the clinical and translational research needed to revive and fully validate the potential of Gallium as a therapeutic for challenging malignancies.
"Once you choose hope, anything's possible."
- Christopher Reeve (Superman)
Glioblastoma (GBM) is one of the most aggressive adult brain tumors. GBM often shows poor response to current treatments. Some MGT can cross the blood-brain barrier and could potentially offer a vital new avenue for therapy.
Hepatocellular Carcinoma (HCC) is the most common form of liver cancer. HCC is often resistant to systemic therapy, and MGT effects on disrupting metabolic pathways common in rapidly dividing cells, presents a breakthrough therapeutic opportunity.
MGT, have excellent safety profile, is a promising therapy with significant potential to benefit the following patient groups.
Pediatric Oncology : For children, who face long-term developmental and neurocognitive damage from aggressive treatments, MGT offers hope for effective therapy with reduced sequelae, crucials for cancers like Medulloblastoma and Diffuse Midline Glioma (DMG).
Geriatric Oncology : Elderly patients often struggle to tolerate standard chemotherapy. MGT's may lower burden on the body, helping to manage cancer while maintaining a balanced quality of life without the debilitating side effects.
Lawrence R. Bernstein received his B.A. and M.A. from Harvard and his Ph.D. from Stanford. Initially, his research was in the physical chemistry and metal geochemistry but later shifted to metal biochemistry and metal-based therapeutics, applying his geochemical knowledge to develop treatments for cancer, infectious diseases, including inflammation and pain. His recent work focuses on the biochemistry and medicinal chemistry of Gallium.
Senior Research Scientist at Stanford University, focusing on improving liver cancer diagnosis and treatment using bioinformatics and genomics. Originally from Singapore, she earned her doctorate from the University of Nottingham and completed postdoctoral training in molecular pharmacology at Stanford. She leads various projects in oncology drug development, experimental therapeutics, and drug repositioning.
Medical Bioinformatics Engineer with experience working with researchers and managing clinical trials. Former Director at Deloitte and Commercialisation Senior Business Partner at UNSW, bringing deep expertise in translational research, and innovation strategy.
Scientist & Entrepreneur committed to fostering collaboration and making substantial contributions to the advancement of new medical research. Currently, also involved in the development of a pioneering medical innovation that has been recognized with the prestigious US NASA iTech Award.
IMPORTANT: Before you join, please note that members of the group do not give, or purport to give, any medical advice and the information offered is for general educational purposes only. For further details please read our DISCLAIMER on our Terms and Conditions.
The medical research collaboration is operated by IMMUNOGEX PTY LTD (ABN 88 653 253 448), trading as MedResearch, a Sydney-based research and development company specialising in Life Sciences and Medical Technologies.
Contact
info@medresearch.com.au
+61 414 456 796
4/27 Rose Cres Regents Park, NSW 2143
Copyright Ⓒ 2025 MedResearch
